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Abstract
Process Analytical Technology (PAT) became a well-defined concept within the phar-
maceutical industry as a result of a major initiative by the FDA called “Pharmaceu-
tical cGMPs for the 21st Century: A Risk-Based Approach.” The FDA defines PAT
as “a system for designing, analyzing, and controlling manufacturing through timely
measurements (i.e., during processing) of critical quality and performance attributes
of raw and in-process materials and processes, with the goal of ensuring final product
quality.” The biotechnology industry has started incorporating PAT in manufactur-
ing, because of regulatory pressure and because the previous blockbuster-oriented
business model is becoming less viable.
This thesis proposes a methodology for evaluating PAT systems and delivers guid-
ance on how to develop and implement them to effectively manage risk in biopharma-
ceutical manufacturing. The methodology includes guidance regarding identifying op-
portunities, evaluating and implementing novel analytical technology, appropriately
applying acquired data, and managing change associated with PAT implementation.
Experimental results from a novel PAT system that acquires light scattering and
UV absorbance data to control chromatography during large-scale manufacturing
are presented as a case study. The case study follows the methodology to show
how a system optimized for a laboratory can be scaled for use in biopharmaceutical
manufacturing.
Thesis Supervisor: Allan Myerson
Title: Professor of the Practice of Chemical Engineering
Thesis Supervisor: Roy Welsch
Title: Professor of Statistics and Management Science, MIT Sloan School of Manage-
ment
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Chapter 1
Introduction
1.1 Project Motivation
Historically, the biopharmaceutical industry has focused its operational efforts on ca-
pacity and quality, but that mindset has been changing over the last decade. Revenue
pressures ranging from patent expirations to global competition have driven maturing
biopharmaceutical companies to seek innovative ways to continue delivering value to
shareholders and society. These changes in the industry’s landscape have caused these
companies to turn to a relatively untapped source of competitive advantage: opera-
tional excellence, which includes improved productivity, risk management, and safety.
In more mature industries, companies have significant experience extracting the ben-
efits that operational excellence provides, but biomanufacturing is still in the early
stages of identifying and taking advantage of this source. Process Analytical Tech-
nology (PAT) is one component of the operational excellence toolset that promises to
reduce biomanufacturing costs, enhance quality, and increase process knowledge.
Regulatory agencies have also played a key role in fostering the adoption of Process
Analytical Technology by both the biopharmaceutical and traditional pharmaceutical
industries. In direct response to the hesitancy of pharmaceutical companies to adopt
innovative operational paradigms, the FDA chartered an initiative, “Pharmaceutical
cGMPs for the 21st century - A risk based approach,” through which it formally
communicated guidance to encourage the future use of PAT in bioprocessing. The
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FDA is not alone, however, as other agencies such as the International Conference
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) and the European Medicines Agency (EMA), among others, have
independently issued guidance regarding PAT.
Many pharmaceutical companies have chartered efforts to incorporate principles
of Process Analytical Technology into their operating organizations, but at the time
of this writing these efforts have not yet achieved the results and widespread adoption
originally envisioned. Several factors have influenced this, including the difficulty of
making significant changes to existing pharmaceutical operating facilities, the chal-
lenges of changing industry and corporate culture, and the need to develop organiza-
tional capabilities to effectively integrate PAT in biopharmaceutical operations.
1.2 Problem Statement
The current interest in Process Analytical Technology has spurred a spate of new
tools and systems from both entrepreneurial ventures and established companies. In
addition, biomanufacturers are evaluating the potential of adapting methods formerly
confined to research applications to use as PAT in bioprocessing. In spite of the ad-
vent of these novel technologies, biomanufacturers have encountered the problem of
understanding precisely what problems PAT needs to solve and which applications
will yield benefits in their processes with their products. Consequently, many organi-
zations have chartered working groups and departments to clarify how to best address
perceived shortcomings.
This research intends to aid in resolving this problem by providing a methodology
for biomanufacturers that can assist in identifying, evaluating, and implementing
currently available PAT. We also intend to highlight opportunities where a PAT
solution could be engineered from current technology, and areas where PAT realization
lies a few years in the future. In an effort to lend credibility to this research, a case
study of the development of a particular PAT system is included to demonstrate
how a laboratory concept can be converted to an implementable biopharmaceutical
14
manufacturing solution.
1.3 Thesis Statement
The thesis proposed in this work is two-fold. First, it asserts that a structured method-
ology, detailed herein, for incorporating PAT in biopharmaceutical manufacturing
will yield the benefits of reduced costs, enhanced quality, and increased knowledge
associated with effective operational excellence. This structured approach focuses
on identifying commercially available systems to satisfy the defined needs, assessing
where gaps exists, making plans to fill the gaps, and then prioritizing development
efforts.
Second, the thesis defends the aforementioned approach by proposing an example
of PAT, which includes a novel approach for analyzing and controlling chromatogra-
phy to a desired level of aggregated protein species in a biomanufacturing process.
This example will also demonstrate preliminary evidence of the system’s benefits,
while including discussion of areas of further research and development.
1.4 Research Methodology
This research was conducted primarily at Amgen, Inc., in Thousand Oaks, CA, and
the large-scale experiments for the PAT system were carried out in a pilot plant facil-
ity on Amgen’s campus. The entire engagement with Amgen from project concept to
completion was 6 months. Because of the relatively compressed time frame, this re-
search is not intended to be a comprehensive body of research comprising the entirety
of PAT in biomanufacturing. Rather, it is intended to use a representative case study
in coordination with a review of the literature regarding PAT in biomanufacturing
to support the thesis presented. The approach taken to the research was a cycle of
the Plan-Do-Check-Act (PDCA) continuous improvement approach popularized by
Deming. We consider this approach appropriate because undertaking the research
with this methodology encourages the cycle of continuous improvement to carry on
15
Figure 1-1: Plan-Do-Check-Act framework for our research
beyond this particular thesis. A brief description of the major activities undertaken
in the Plan-Do-Check-Act framework is shown in Figure 1-1, and specific steps re-
garding the PDCA approach for the case study portion of this work will be further
defined.
During the Plan phase, the novel framework for incorporating PAT in biomanu-
facturing was developed based on interviews and meetings with over 20 scholars and
professionals involved with PAT from various areas of expertise. These scholars and
professionals include experts knowledgeable in management, traditional—or “small
molecule”—pharmaceutical operations, biopharmaceutical operations, process con-
trol and automation, optical science, protein aggregation, chromatography, biological
analysis, chemical analysis, and others. Previously published literature was reviewed
to understand the relevant research, with an emphasis on the areas of Process An-
alytical Technology, biomanufacturing, protein aggregation, online process analysis,
and biopharmaceuticals. Additionally, the scope and objectives of the research were
aligned with the project objectives of Amgen, the sponsoring entity, prior to execut-
ing research and development. In all cases, data and information are presented only
in sufficient detail to substantiate and illustrate the results without compromising
16
information deemed proprietary by the sponsor.
In the Do phase, a team was assembled with representation from functional exper-
tise areas including light scattering detection, process control, protein purification,
equipment engineering, wiring, and input/output (I/O) for the novel PAT system.
The PAT framework also integrated input from the aforementioned team and in-
cluded input from project management leaders, quality leaders, and manufacturing
leaders responsible for incorporating PAT into their operating organizations. The ef-
forts of the team were coordinated to best meet the needs of the project. The research
was executed as described in the PAT framework and case study.
For the Check phase, performance was measured by whether the novel PAT system
could satisfactorily measure and control the amount of aggregated protein species in
the chromatography pool. In addition, the PAT framework was measured on its
merit as a simple communication tool and plan for deployment in a biomanufacturing
organization intending to incorporate PAT principles in operations.
In the Act phase, results were communicated to the sponsor company and pre-
sented for this thesis. These communications are intended to provide insight into
future opportunities for PAT in biopharmaceutical manufacturing.
The primary test of this research methodology is the specific example regarding
manufacturing chromatography column analysis and control described herein and the
applicability of the PAT framework. The data for the chromatography experiments
were collected from pilot-scale runs of a development-phase therapeutic protein—
specifically a monoclonal antibody—in a facility dedicated to development and ex-
perimentation at scales larger than a typical laboratory can offer. These large-scale
experiments serve as a basis for the claimed applicability of these results to other
large-scale biopharmaceutical manufacturing processes.
1.5 Thesis Overview
This thesis is segregated by chapter, and the contents of each can be briefly described
as follows:
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Chapter 1 is an introduction, which includes the project motivation, problem
statement, central thesis statement, and research methodology. We set forth the
reasons for conducting this research and in the environment in which the research
was carried out. Furthermore, we detail how the research was executed and what
central hypothesis is to be tested.
Chapter 2 gives a background on topics relevant to the research including a lit-
erature review. The chapter includes descriptions of the biopharmaceutical indus-
try, biomanufacturing, and Process Analytical Technology (PAT). These descriptions
serve as a way to link the early history of biotechnology to biopharmaceutical man-
ufacturing, and then to describe how biopharmaceutical manufacturing transitioned
to an area of active operational improvement from a relatively inefficient—in terms
of operations—early stage. In addition, the role of PAT in improving the state of
biopharmaceutical manufacturing is explored.
Chapter 3 specifically describes the research findings related to incorporating PAT
in biopharmaceutical manufacturing. It details a structured approach to developing
and implementing PAT, and it includes a detailed example of an implementation in
a large-scale experimental facility.
Chapter 4 outlines an investigation into possible future PAT development op-
portunities. It reviews current research in three primary areas: advanced optical
technologies, microscale and nanoscale devices, and sources from other industries and
disciplines. This chapter highlights key areas where PAT systems could be developed
in the future.
Chapter 5 contains our recommendations for biopharmaceutical industry members
who seek to incorporate principles of PAT in their operations. The emphasis is on
identifying straightforward initiatives that industrial organizations can undertake to
improve operational excellence.
Chapter 6 is a conclusion, which summarizes the body of work presented. It
includes the implications of this research on the biopharmaceutical industry at large.
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Chapter 2
Background and Literature Review
2.1 Biotechnology and the Biopharmaceutical In-
dustry
The foundation of the biopharmaceutical industry is biotechnology, which is the use
of naturally occurring or engineered living organisms to generate a desired output.
Humans have employed principles of biotechnology, in the broadest sense of the term,
to achieve a variety of ends for millennia, such as raising cows for their milk and
cultivating crops. Therapeutic biotechnology involves employing the principles of
biotechnology for improving an organism’s quality of life, and a significant advance
in the progress of therapeutic biotechnology occurred in the 1700s, when vaccines
and vaccine production were developed. These vaccines eventually wiped out many
widespread diseases. However, vaccination was limited to a set of diseases that could
be isolated, inactivated, and injected in sufficient quantities to provide immunological
defense to the targeted virus. In addition to the small set of immunizable disease us-
ing this technology, it was costly and inefficient to scale production. Because of these
limitations, early vaccines are not generally included in the definition of biopharma-
ceuticals. The accumulated human experience and biotechnological knowledge from
crops to vaccines ultimately did give rise to the modern biopharmaceutical industry.
Biopharmaceuticals, or biologic medical products, are therapeutic medicines pro-
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duced by the cells of a living organism. Biopharmaceuticals differ from traditional
pharmaceuticals in at least three key ways: production process, molecular structure,
and method of patient delivery. The manufacturing process will be treated at length
in a later section, but the most unique aspects of biopharmaceutical production are
the steps required to culture organisms that produce the desired therapy. In essence,
the production of the biopharmaceuticals is based on the ability to program an organ-
ism such as a cell, to rapidly and reliably replicate itself and then produce the desired
molecule. In contrast, traditional “small molecule” manufacturing processes do not
rely on a programmed organism as a means of production, but rather rely on reactions
and separations of purified reagents to yield the desired product. The biopharmaceu-
tical molecule is often significantly larger than that of a traditional pharmaceutical
as shown in Figure 2-1∗, and the resulting molecular complexity causes its shape and
arrangement to impact its function within the human body as much as its molecular
composition.
Figure 2-1: Illustration of therapeutic molecule sizes (not exact scale) which are,
from left to right, a monoclonal antibody, epoetin alfa, loratadine, and acetylsalycylic
acid (aspirin)
Because of this large, complex structure, biopharmaceuticals tend to be less stable
∗The first two molecules in Figure 2-1, the monoclonal antibody and epoetin alfa, are considered
biopharmaceuticals, while the latter two are considered traditional pharmaceuticals.
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and less able to penetrate pores within the human body than traditional pharmaceu-
ticals over a given period of time. Therefore, biopharmaceuticals are most often
delivered parentally, or by injection, while traditional pharmaceuticals are often de-
livered orally. In spite of these differences, there are exceptions to these generalities,
so they should be considered as guidance rather than strictly defined categories. Per-
haps due to the difficulty in achieving economies of scale with existing development
and manufacturing methods, until the middle of the twentieth century most synthetic
therapies were developed and manufactured using more chemical, or “small molecule”
methods.
Biopharmaceuticals as a class of therapies include all therapeutic products enabled
by recombinant DNA and synthetic antibody technologies. Recombinant DNA tech-
nology, including the discoveries that led to it, was the major scientific breakthrough
that facilitated the delivery and development of a variety of synthetic biopharmaceu-
ticals at large scales. Recombinant DNA is defined as any synthetic DNA molecule,
including molecules formed by separating and combining portions of DNA from one
or various organisms. As discussed, prior to recombinant DNA technology, the only
systematic and scaleable way of developing and manufacturing new human therapies
was through the use of chemical processes or inactivating viruses. Therefore, desired
pharmaceutical therapies, including proteins and antibodies, would either have to be
synthesized chemically or extracted from organisms in vivo. The former continues to
be cost prohibitive as it pertains to proteins and antibodies, and while the latter is
of a more biological nature, its scale and scope are limited by the ability to discover
existing proteins and antibodies of therapeutic significance through trial and error.
One of the first methods developed for the successful creation of recombinant
DNA molecules was published in 1972,1 and attempts to produce biopharmaceuticals
using this new technology followed close behind. After several years of developments,
these attempts culminated in a major success: the first biopharmaceutical to be
developed, engineered, and manufactured using a biological—rather than chemical—
paradigm for development and production. This first biopharmaceutical approved
for human use was a synthetic human insulin analog, Humalog (insulin lispro), devel-
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oped through the collaboration of Genentech Inc. and Eli Lilly and Company.2 This
technical and commercial breakthrough paved the way for significant investment in
the biotech industry, which hit another milestone when Epogen® (epoetin alfa), by
Amgen, became the first blockbuster† biopharmaceutical.3
The most common cells engineered to produce recombinant DNA protein thera-
peutics are derivatives of the mammalian cells of Chinese hamster ovaries (CHO) and
the bacterial cells of E. coli.4, 5 For industrial processes that generate biopharmaceu-
ticals on a large scale, the product is most commonly a protein, such as epoetin alfa.
A significant subset of biopharmaceutical proteins is synthetic antibodies, including
monoclonal antibodies such as adalimumab.
Monoclonal antibody technology for use in human therapeutics was the second
major scientific breakthrough enabling the biopharmaceutical industry’s growth. A
monoclonal antibody is a synthetic, Y-shaped molecule derived from a single cell line
that preferentially binds to a specific region of an antigen, which is a compound that
is often a key factor associated with a disease. This binding is a critical part of the
immune response for eliminating the threat of infectious bacteria and viruses. The
development of monoclonal antibodies provided researchers with another broad plat-
form to extend therapeutic research beyond replicating proteins that were biologically
similar to those present in the human body, since monoclonal antibodies could be en-
gineered to specifically target an antigen of interest. After many years of research
and development, the first monoclonal antibody approved for human therapy was
muromonab‡ in 1986.6
In summary, the combination of recombinant DNA and monoclonal antibody tech-
nologies provided the biopharmaceutical industry with greater ability to synthesize
proteins with desired structures, properties, and therapeutic effects. Within this ex-
panded realm of possibilities scientists have developed new and improved treatments
for a variety of illnesses. Since the approval of synthetic human insulin, a series of
successful biopharmaceuticals has generated a rapidly growing, profitable industry,
†“Blockbuster” indicates a therapy that has annualized revenue of over one billion dollars.
‡Modern naming conventions stipulate that the scientific name of a monoclonal antibody end in
“-mab”, but these conventions were not in place when muromonab was developed.
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Protein Name(s) Trade Name(s)
Revenue
($B)
Company
Adalimumab Humira 7.9 Abbott
Etanercept Enbrel 7.4 Amgen, Pfizer
Infliximab Remicade, Simponi 5.8 J&J, Merck & Co.
Bevacizumab Avastin 5.7 Roche
Trastuzumab Herceptin 5.7 Roche
Filgrastim,
Pegfilgrastim
Neupogen, Neulasta 5.2 Amgen
Insulin glargine Lantus 5.2 Sanofi-Aventis
Interferon beta-1a Avonex, Rebif 4.9
Biogen Idec, Merck
KGaA
Ranibizumab Lucentis 3.7 Novartis, Roche
Table 2.1: Top-selling biopharmaceutical products of 2011 - data gathered from
2011 public financial reports
as shown by Table 2.1§, which depicts the top-selling biopharmaceutical products of
2011.
2.2 Biosimilars
In addition to developing and offering different, competing treatments for similar ail-
ments, the idea of developing and offering biologically similar treatments, or biosimi-
lars moved from concept to possibility when patents on the earliest biopharmaceuti-
cals expired. The advent of biosimilars could significantly impact the biopharmaceu-
tical industry, because the business case for biosimilars is based on price competition.
Therefore, developers and producers of biosimilars would have incentives to minimize
facility and operating costs to the extent possible. Yet biosimilars have not been
developed and approved in quantities comparable to generic versions of traditional
pharmaceuticals. This lack of competition for products whose patents have expired
has led to intensive communication between governments and the biopharmaceutical
industry because societies tend to view this as a market failure.
§Different products may be developed to treat the same or similar conditions. For example, the
top three products in Table 2.1, adalimumab, etanercept, and infliximab are all approved to treat
rheumatoid arthritis and other autoimmune diseases.
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At least one major reason behind the lack of competition is that the manufactur-
ing equipment, host cell line, process design, and raw materials used for a particular
biopharmaceutical are more important contributors to its therapeutic efficacy than
those of a traditional pharmaceutical, which relies primarily on its molecular compo-
sition for efficacy.7 Another major reason for the lack of commercial biosimilars was
the absence of a regulatory pathway for the approval of these therapies. To address
perceived regulatory shortcomings, the European Medicines Agency (EMA), issued a
procedure for the approval of biosimilars in 2005.8 Then, in 2012, the FDA issued its
own guidance.9 Since that time, a number of companies have announced their intent
to capitalize on the commercial opportunity presented by biosimilars. These efforts
generally have taken the form of an established biopharmaceutical company with a
large, developed marketing and sales function partnering with experienced generic
pharmaceutical manufacturers. For example, Pfizer and Biocon announced such a
partnership in 2010, and Amgen and Watson followed suit in 2011.10,11
These partnerships lend credibility both to the claim that biosimilars are signifi-
cantly less expensive to develop than original biopharmaceuticals, and that biosimilars
increase pressure on biomanufacturing companies to explore opportunities to oper-
ate more efficiently. By some estimates, biosimilars cost $100M to $200M to develop,
whereas novel biopharmaceuticals cost a significantly higher $1.2B.12 Even though the
future state of biosimilars is unclear at the time of this writing, the intent of stim-
ulating increased competition could have a significant impact on biopharmaceutical
manufacturing as companies look for cost effective ways to develop and manufacture
biosimilars to compete with proven, profitable products.
While the biopharmaceutical industry continues to innovate, progress, and de-
liver therapies to patients, increasing competition including the threat of biosimilars
is driving companies to continue seeking opportunities to deliver value to patients
and shareholders. Maturing products and technologies have led to a need for more
efficient operating processes, not only to meet capacity constraints, but also to begin
adoption of continuous improvement principles for which other mature manufacturing
industries are known.
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2.3 Biopharmaceutical Manufacturing
Although biopharmaceutical manufacturing, a subset of biomanufacturing, shares
some characteristics with certain other liquid and solid manufacturing processes such
as fermenting yeast and oil refining, it also includes a set of both unique and relatively
immature processes, especially as compared to traditional pharmaceutical manufac-
turing.
Because biopharmaceutical manufacturing is still a somewhat novel process at
large scales, an attempt will be made to describe the primary steps here. In reality, a
variety of manufacturing processes for engineered recombinant proteins are in use or
under development, including cellular processes and products derived from transgenic
organisms such as goats, chickens, and plants. This description focuses on the cellular
manufacturing platforms using mammalian (i.e. CHO) or bacterial (i.e. E. coli) cells,
which are by far the most common model for producing biopharmaceuticals.
The biopharmaceutical manufacturing process begins with a small vial taken from
a set of cells engineered to produce the desired product, also known as the cell bank.
The contents of the vial are then placed into the cell culture process, where the en-
vironmental parameters and nutrient concentrations are manipulated to encourage a
desirable rate of cell replication. During cell culture, an optimum level of parame-
ters including acidity, oxygen level, carbon dioxide level, and nutrient presence are
maintained in a bioreactor. As a critical mass of cells is cultured, the role of the cell
changes from cell reproduction to protein production. This shift can be induced by
changing the environmental conditions in the bioreactor.
The cells produce proteins until a desired amount of protein per unit volume, or
titer, has been achieved. At this point, the process focus again shifts, and it now
emphasizes protein isolation and purification. Newly generated therapeutic proteins
share the bioreactor volume with cells, cell waste, nutrients, and a variety of other
compounds from which they must be separated. The first major separation of proteins
from cells is generally referred to as harvest, and the remainder of the separation
process is called purification. Harvest can be performed in a centrifuge or filter that
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Process Step Description Equipment Desired Outcome
Cell Culture Generate cells Bioreactor
Critical mass of
protein-producing
cells
Production
Produce
desired protein
Bioreactor
Target protein con-
centration
Homogenization
(bacteria only)
Break cell mem-
branes to expose
protein
Homogenizer Ruptured cells
Harvest
Separate protein
from cell matter
Centrifuge
Proteins separated
from cell matter
Purification
Separate protein
from other impuri-
ties
Chromatography
columns, filters
Purified protein in
solution
Table 2.2: Major steps in the drug substance portion of biomanufacturing
separates the cells from the proteins. Afterward, the purification steps tend to be a
series of chromatography operations, which involve passing the process fluid through
columns packed with beads of resin that continue to isolate the desired proteins
from undesirable compounds such as aggregated proteins, undesired proteins from
the host cell population, and particulates. Then the process fluid is pumped through
final filters to remove microparticles and viruses. The result of this process is a very
pure, concentrated, protein solution called drug substance. The major steps leading
to drug substance are outlined in Table 2.2.
Now that the protein is isolated, the next step is formulation, or adding other
compounds to stabilize the protein or improve therapeutic characteristics such as
residence time in a patient. Formulation may be followed by another filtration step.
Finally, the drug product vials or syringes are filled, labeled, and packaged to be
transported through a “cold chain,” or temperature-controlled supply chain, to a
location where they can be administered to a patient.
It is important to note that most of the biomanufacturing process often occurs
in batches, where each step is conducted independently of any other. Furthermore,
there are various stages during the process, such as after completing a batch of drug
substance, where the product may be subjected to a combination of freezing, storage,
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Process Step Description Equipment Desired Outcome
Formulation
Add compounds to
stabilize and adjust
potency
N/A
Potent and effective
biopharmaceutical
Fill/Finish
Segregate into sepa-
rate doses (freeze if
necessary)
Filling machine,
freeze dryer
Properly dosed and
frozen vials
Package/Seal
Seal vials, boxes,
and label
Capping and la-
beling machine
Properly labeled
and sealed contain-
ers
Cold Chain
Maintain tempera-
ture during trans-
port
Insulated pack-
aging, refriger-
ated vehicles
Effective therapy
delivered to patient
Table 2.3: Major steps in the drug product portion of biomanufacturing
and transportation as needed. While these descriptions comprise most of the major
biomanufacturing stages involved in directly producing and delivering the therapeutic
protein, there are also many steps involved in preparing raw materials, managing
utilities, quality control, and so on.
In conclusion, biomanufacturing is currently composed of a series of often discrete
steps from cell culture to purification to final formulation and packaging. For a more
detailed, yet introductory, explanation of biomanufacturing, the author recommends
Manufacturing of Pharmaceutical Proteins: from technology to economy by Stefan
Behme. Even though biomanufacturing as described in Behme’s work is a validated
process for protein production, these processes are constantly undergoing development
and improvement in a variety of areas, including improved raw material usage, higher
titers and concentrations, faster cycle times, increased continuous processing, and
more effective process analysis and control.
2.4 Process Analytical Technology
Process analysis can be a broadly defined concept, and we will define it as equipment
and instrumentation employed in analyzing an attribute or set of attributes of a
flowing liquid or solid process. Typically, these process analyzers use one or more of a
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variety of physical principles to measure a quantity (i.e. temperature), and then send
a signal of some form to an interface where it can be understood (i.e. a reading in
degrees Celsius) and acted upon by a human or automated operator. We will consider
such analyzer-based control an essential part of any Process Analytical Technology
(PAT) system. The system presented in the case study has a very simple “on/off”
feedback control mechanism, while other systems might employ more sophisticated
control schemes.
As in most industrial processing facilities, biomanufacturing facilities currently
contain a variety of quality laboratories, process instrumentation, and other systems
to ensure the manufacture and delivery of a quality product to the end user. However,
the pharmaceutical industry (including the biopharmaceutical industry), has histori-
cally been slower than other industries to adopt new technologies and processes that
result in higher quality products and more efficient manufacturing.
2.4.1 Regulatory Initiatives
At least one reason for this slow adoption was due to perceived regulatory uncer-
tainty, so the FDA chartered an initiative called “Pharmaceutical cGMPs for the
21st Century: A Risk-Based Approach” in 2002, which was intended to encourage
innovation within the pharmaceutical industry in hopes of achieving higher quality at
lower costs. Two years later, a sub-initiative was launched called Process Analytical
Technology (PAT), which was encapsulated in a document entitled “Guidance for
Industry PAT—A Framework for Innovative Pharmaceutical Development, Manufac-
turing, and Quality Assurance.” It defines PAT as “a system for designing, analyzing,
and controlling manufacturing through timely measurements (i.e., during processing)
of critical quality and performance attributes of raw and in-process materials and
processes, with the goal of ensuring final product quality.”
Understanding that a development effort is only sustainable if its implementa-
tion provides measurable benefit, the FDA enumerated areas where PAT is likely to
provide returns, which are shown in Figure 2-2.13 Then, in 2008, the International
Conference on Harmonisation of Technical Requirements for Registration of Phar-
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maceuticals for Human Use (ICH) released guideline Q8 for pharmaceutical develop-
ment. This guideline formally introduced the concept of quality by design (QbD) to
the pharmaceutical industry and enumerated PAT as a central tenet of pharmaceuti-
cal manufacturing. However, ICH Q8 altered the concepts of quality by establishing
QbD as a lifecycle-oriented development framework with design of experiments, PAT,
process knowledge acquisition, and risk management as its main components.14
 Reducing production cycle times by using on-, in-, and/or at-line measure-
ments and controls
 Preventing rejects, scrap, and re-processing
 Real time release
 Increasing automation to improve operator safety and reduce human errors
 Improving energy and material use and increasing capacity
 Facilitating continuous processing to improve efficiency and manage vari-
ability
Figure 2-2: Expected benefits of PAT according to the FDA
Since the debut of pharmaceutical PAT in 2004 and its later association with QbD
in 2008, PAT has understandably become a topic of interest throughout the industry.
Matthew gives an accessible explanation of the relationship between QbD and PAT,
while noting that regulatory initiatives for QbD and PAT were initially developed
with traditional pharmaceuticals in mind. She also estimates the economic benefits
of deploying QbD in the biopharmaceutical industry, substantiating the notion that
QbD and PAT can deliver a cost effective impact to adopters.15 Rathore and Win-
kle indicate that the Office of Biotechnology Products (OBP) within the FDA and
similar departments at other global regulatory organizations are now responsible for
encouraging QbD and PAT adoption within the biopharmaceutical industry. Further-
more, they specify that two of the greatest challenges faced by OBP and industry
in the future are utilizing a common terminology and ensuring personnel from all
organizations are appropriately trained to handle the imminent changes.16
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In spite of these challenges, the regulatory agencies involved in defining and sup-
porting the adoption of PAT have clearly injected interest and development in the
area. This heightened interest has galvanized the development of many new technolo-
gies.
2.4.2 Technical Developments
One of the difficulties of discussing the topic of Process Analytical Technology in
biomanufacturing is that the list of possible systems and ideas is vast. This could
partly be due to the increased scrutiny given to PAT in recent years, and it also may
lend credibility to the notion that many systems for measuring biological attributes
continue to be insufficient for characterizing the key attributes of complex biopharma-
ceutical products. In order to provide some coherence to development efforts, several
attempts have recently been made to review and categorize PAT developments for
biopharmaceuticals.
One review, by Pitka¨nen et al. attempts to list “the state of the art in on-line
bioprocess monitoring.” Their review emphasizes recent inventions and innovations
that are targeted exclusively for use on the bioprocess line. They also categorize
systems by their measurement principle. The list is quite broad, but the systems are
not necessarily PAT in their truest sense due to a lack of control systems in many
instances. However, the review provides a look at the variety of analyzers on the
market, which is an important component of any PAT system.17
A second, thorough, review is given by Rathore and others focusing on the topic of
chemometrics in bioprocessing. The authors briefly explore the similarities between
systems used in traditional chemical processing, traditional pharmaceutical process-
ing, and applications in bioprocessing. By definition, chemometrics covers chemical
analyzers such as spectroscopy, spectrometry, and chromatography, which accounts
for a large part of the available biomanufacturing analysis systems. In this overview,
the authors also emphasize the need to make effective use of increasing amounts of
PAT-generated data.18
Ka¨nsa¨koski et al. give an in-depth treatment of biometrics, or the use of biologically-
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oriented measurement principles, in their review of areas where PAT needs to be
developed. This review focuses on the cell culture and protein production phases of
biomanufacturing, which is where biometric PAT applications would have the most
impact. This is because the cell culture and protein production phases in the bioreac-
tor have a longer operational time frame and a process fluid with high concentrations
of biological species.19
Junker and Wang agree that appropriately applying PAT information from exist-
ing technologies can aid in bioprocess control, but they also encourage the continued
development of new technologies that embody the principles of simplicity and ro-
bustness championed by Daniel I.C. Wang, Institute Professor at the Massachusetts
Institute of Technology, whose pioneering achievements in computer-controlled fer-
mentation methods laid the groundwork for pharmaceutical PAT.20 Clearly, there is
no shortage of opportunities both to incorporate existing technologies and develop
new technologies for implementation as PAT systems.
The abundance of technology available and in development for use as PAT sys-
tems poses a conundrum as to how it can be effectively deployed in biopharmaceutical
manufacturing. To aid in this effort, Garber outlines two essential business processes
for creating and managing a PAT program within an organization. First, the PAT
implementation process outlines criteria and decision-making around screening oppor-
tunities, identifying areas for potential PAT implementation, evaluating impact, and
initiating the project to implement. The second essential process involves sustaining a
PAT program once it is in place through a regular reporting structure. These discus-
sions illuminate the fact that any innovative biomanufacturer seeking to embrace or
improve PAT needs to lend momentum to such efforts through appropriate business
processes and organizational structure.21
With an appropriate implementation program in place, one of the more intrigu-
ing prospects for PAT—also identified in Figure 2-2—is the facilitation of continuous
processing. Warikoo et al. present a system for the continuous production of biophar-
maceutical APIs, which is notably enabled by the use of a PAT system based on UV
absorbance. As they indicate, the promise of continuous processing rests primarily on
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its ability to reduce costs if effectively deployed, as has been demonstrated in various
other industries.22 While the method presented is not an “end to end” continuous
biopharmaceutical production concept—in contrast to the concept demonstrated by
the Novartis-MIT Center for Continuous Manufacturing23 for small molecules—it is a
promising possibility for overcoming a significant barrier to integrating the cell culture
and purification steps of drug substance biomanufacturing.
2.5 Differences Between This and Other Research
The first difference between this and other research is that we present a method
for approaching PAT implementation in an organization that emphasizes the entire
analytical capability of the biomanufacturing plant, including in-process analyzers and
off-line analyzers in all facility labs including quality control, in-process testing, and
microbiological testing. Most research to date approaches PAT as a way to improve
process control on a unit operation by unit operation basis, with little attention
devoted to how appropriate use of PAT goes beyond a single unit operation toward
facilitating continuous biomanufacturing or real-time release. While the scope of this
research is limited to the portion of biomanufacturing that takes place in a facility
devoted entirely to drug substance production, it provides evidence that PAT is at a
sufficiently mature stage to provide tangible benefits. Gains from PAT can be sought
by integrating improved raw material quality control, in-process control and release
testing from raw materials to patient delivery.
The second difference is that we present a novel PAT system for analysis and
control of the first clarifying chromatography step of biopharmaceutical manufactur-
ing using fast detection of low levels of aggregate proteins at a manufacturing scale.
This method couples static light scattering with UV spectroscopy. Previous work has
also demonstrated improved chromatography control at manufacturing scales using a
high pressure liquid chromatography (HPLC) analytical system interfacing with the
process to a similar end.24,25 The relative merits of the novel PAT system we present
compared to other systems are discussed.
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Chapter 3
Identifying, Evaluating, and
Implementing Effective PAT
Solutions
3.1 PAT Strategy
In order to develop a PAT strategy for the operational organization of a biophar-
maceutical manufacturer, it is critical to clearly convey the key rationale for its de-
ployment. A simple statement governing PAT strategy, shown in Figure 3-1, can be
constructed by combining aspects of the definition, examples, and benefits of PAT.
PAT manages product risk throughout the pharmaceutical manufacturing value
chain through the innovative, effective acquisition and application of data
Figure 3-1: PAT strategy statement
Ultimately, PAT is about using data to manage risk during manufacturing. The
data comes from validated and documented sources such as process analyzers and
less rigorously documented sources such as human observation. The acquired data
is then applied to manage risk through automated and human feedback mechanisms.
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Therefore, a robust biopharmaceutical manufacturing process is a process that can
accommodate the consequential and inconsequential variability inherent in manufac-
turing while generating an effective product with acceptably low risk of failure. For
this reason, PAT is as much about understanding what attributes of the product
and process are consequential as it is about developing technology to quantify those
attributes.
3.2 PAT Opportunity Identification
As with most manufacturing facilities, biopharmaceutical manufacturing plants have a
variety of areas and laboratories devoted to diverse tasks such as production, receiving
raw materials, quality control, and shipping product. Each of these areas has a set
of employees, processes, systems, and technologies that have been selected based on
their capability to supply sufficient product to meet patient needs. These employees,
processes, and systems are responsible for acquiring and applying data to ensure that
the product is of an acceptable quality. Much of the previous literature around PAT
has focused on the idea that opportunities for PAT can be identified by surveying the
biomanufacturing process and screening the various unit operations for improvement
opportunities. An illustration of this mindset is given in Figure 3-2. Clearly, this
approach can yield benefits, but the maturity of biopharmaceutical manufacturing is
reaching a point where a broader approach grounded in mitigating risk through the
effective use of data is warranted.
Most biomanufacturing operations currently collect significant amounts of data.
The current approach to verifying biopharmaceutical product quality is often a com-
bination of ensuring that the process parameters measured during production remain
within a specified range and verifying that the product meets specified criteria after
being subjected to a battery of oﬄine assays at various stages during the process.
For this reason, current data sources include both online process analyzers and oﬄine
assays. In order to illustrate the type of testing and inspection that goes on in a
biopharmaceutical manufacturing plant, Table 3.1 enumerates examples of various
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Figure 3-2: Unit operation-focused PAT opportunity identification
oﬄine tests, or assays.
There are many other oﬄine assays in addition to those listed in Table 3.1, and it is
clear from the descriptions that the assays inspect characteristics of the protein itself,
the protein solution, and impurities that may be present. Therefore, the numerous
oﬄine assays should also be an important contributor to any PAT strategy as they
are ultimately part of the analytical capability of the plant. Both the data collected
online in manufacturing and oﬄine in the laboratories contribute to the overall picture
of the risk profile of the process and product, so both sources should be utilized and
developed to improve analysis and risk management.
Assay Type Description of Purpose(s)
Size exclusion chromatography
(SEC)
High molecular weight species (or aver-
age molecular weight)
UV spectroscopy Protein concentration
Peptide Map
Confirm peptide makeup of (polypep-
tide) protein
Polymerase chain reaction (PCR)
Detect nucleic acids associated with im-
purities
Enzyme-linked immunosorbent
assay (ELISA)
Protein binds to desired target to help
confirm therapeutic efficacy
Visible inspection
Ensure that no visible defects are
present in liquid
Kinetic limulus amebocyte lysate
(Kinetic LAL)
Detect presence of bacterial endotoxins
Trypan Blue cell count Count number of viable cells
Table 3.1: Examples of common oﬄine assays
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A central tenet of this thesis is that oﬄine assays are another critical dimension for
any PAT identification effort, adding to conventional, unit operation-focused methods
of PAT opportunity identification. These two dimensions of a PAT strategy, shown
in Figure 3-3, suggest a convergence of improving the manufacturing process with
improving oﬄine assays to establish a new generation of biomanufacturing plants
that delivery higher quality products to patients.
This holistic approach also aims to highlight opportunities that exist for imple-
menting continuous processing and real-time release in the hope that these objectives
would increase the efficiency of biomanufacturing. In fact, continuous processing will
increase the number of opportunities to use real-time control and modeling systems
to manage the risk of the operating facility, thus expanding the PAT opportunities
available to be explored. As long as PAT improvements are limited to a single unit
operation, the opportunities to control the process will only be possible within the
scope of each individual unit batch.
Figure 3-3: Two-dimensional strategy for PAT opportunity identification
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This convergence also suggests that PAT solutions will not only come from de-
velopers of technologies with expertise in process analyzers, but also from developers
with expertise in oﬄine assays as they make improvements to their product offer-
ings. In a general sense regarding PAT, oﬄine assays can often be improved in many
ways such as increasing measurement speed, reducing complexity, and improving pro-
cess integration. Process-oriented technologies can often be improved by increasing
sensitivity, enhancing reliability, and measuring new attributes of biological impor-
tance. This leads to the conclusion that some PAT solutions could improve control
of the manufacturing process while simultaneously reducing the need for oﬄine test-
ing. Additionally, improvements to information technology infrastructure and control
systems will facilitate this convergence of technological advancement.
In Figures 3-2 and 3-3, illustrations highlight the difference between approaching
PAT from a perspective exclusive only to unit operation improvements and from a
perspective that includes oﬄine assay capabilities. However, these figures may under-
state the possibilities of using this approach to evaluate other strategic opportunities,
such as raw material quality oﬄine assays, the interaction between drug substance
and drug product operations, stability testing, and so on. Therefore, this framework
should be used to view the biopharmaceutical manufacturing facility as a single, com-
plex, unit operation. This will provide new insight into how improvements can be
made to the overall production process, and not just its constituent operational parts.
Even in cases such as raw materials, combining batch process steps into continuous
flow, and stability testing, the two-dimensional framework can be applied, resulting
in both process technologies and oﬄine tests contributing to opportunities for novel,
effective PAT solutions.
In short, we propose a holistic approach to identifying PAT opportunities that
includes evaluating opportunities both from the manufacturing process and oﬄine
analytical testing. This approach should serve as a complement to previously pub-
lished frameworks based on evaluating single batch unit operations to maximize the
effectiveness of implementing PAT in biopharmaceutical operations. All PAT imple-
mentation opportunities should be carefully evaluated to ensure that they are valu-
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able, given that a holistic approach does not guarantee that all identified opportunities
will provide a benefit. Implementing PAT, continuous processing, real-time release,
and other technical advances could prove to be more cumbersome than beneficial if
conceived and executed ineffectively. Therefore, in order to effectively evaluate those
PAT opportunities that create value, a set of applicable criteria must be established.
3.3 Evaluating PAT Opportunities
An ideal biomanufacturing facility would be able to reliably produce therapeutics that
adhere to quality specifications and ensure effective treatment of patients. All of the
biopharmaceutical’s characteristics that have a measurable physiological impact on
the patient (including physiologically active impurities such as adventitious agents)
would be measured and controlled. The majority of control would take place in real
time, eliminating the need for excessive inspection, scrap, or rework post-processing.13
In addition, the facility would maintain a continuous improvement process, enabling
the improvement of cycle time, yield, and quality from acquiring and applying data.
Not only would this knowledge be applied to improve a single facility, but each suc-
cessive generation of facilities would improve on the prior generation. In this way,
the biopharmaceutical manufacturing facility would effectively manage product risk.
Therefore, any PAT opportunity should be measured on its ability to deliver
progress toward an ideal biomanufacturing facility given the time and cost required
to develop it. In this thesis, we propose five categories to evaluate the costs and
benefits provided by a PAT system, which are shown in Figure 3-4. These five metrics
are one possible way to categorize the potential PAT benefits stipulated by the FDA
as referenced in Chapter 2. The use of these categories is also influenced by the
quality management principles championed by W. Edwards Deming and Joseph Juran
and the concepts of the efficient plant set forth by Eliyahu Goldratt. These metrics
can be viewed as a means to quantify the gain associated with any PAT-related
implementation, and can conversely be viewed as a way to measure the reduced cost
of poor quality of such an implementation. Just as the gain from implementing PAT
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should be measured by evaluating its contribution to the four enumerated categories
of benefits, the cost of implementing PAT must also be measured to ensure a net
overall benefit. Key costs include the cost to develop, the time to develop, and the
ongoing operational cost.
Quality
Producing product within specified ranges for a set of measurable attributes
Cycle Time
The time required to complete production of a given quantity of product
Yield
Quantity of product manufactured as a percentage of process inputs
Process Knowledge
Acquired knowledge that can be understood and applied for future improve-
ments
Cost
The total cost of developing and implementing the opportunity
Figure 3-4: Criteria for evaluating PAT opportunities
In summary, the criteria of quality, cycle time, yield, process knowledge, and cost
will serve as benchmarks for whether a PAT system is delivering a net benefit. With
a framework in place to identify and evaluate PAT opportunities, we will now proceed
to a case study of a novel PAT system. In the case study, the novel technology will
be presented and considered in light of this framework.
3.4 Case Study: A Novel PAT System for Analyz-
ing and Controlling Chromatography
3.4.1 Background
Protein aggregation during biopharmaceutical manufacturing is not uncommon, and
is an area of focus for research because the presence of aggregates may cause problems
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during delivery and use. As biopharmaceutical proteins have become more prevalent
therapies, the discovered varieties and mechanisms of protein aggregation have also
increased. In this work we will take the term protein aggregates, or aggregation,
to mean any agglomeration of two or more protein monomers. A monomer will be
defined as the smallest effective therapeutic molecule.
Cromwell et al. indicate that protein aggregation is undesirable because small,
invisible aggregates may cause an adverse immune response in the patient, and large
aggregates may cause delivery problems during injection. In either case, aggrega-
tion can occur when protein monomers denature, or unfold, exposing previously in-
accessible covalent binding sites. Weaker, reversible, bonds can also form through
electrostatic or dipole-dipole interactions associated with small changes in protein
structure. In short, the size and complexity of protein molecules provide for a variety
of pathways that can facilitate protein aggregation. Although we will treat protein
aggregation here as unfavorable, some protein therapies are stable only when two
protein molecules are covalently bound. Furthermore, Cromwell and her coauthors
point out that many factors can influence and drive aggregation, including “tempera-
ture, protein concentration, pH...freezing, exposure to air...[and] mechanical stresses.”
Since many of these variables are inherent in the biopharmaceutical manufacturing
process, aggregation can occur simply as a result of processing.26
Therefore, the ideal biopharmaceutical manufacturing product consists of a solu-
tion containing proteins only in monomer form, with minimal aggregate impurities.
The mechanisms and sources of aggregation are still not well understood in detail, so
they can be difficult to control. Consequently, a number of methods have been de-
veloped to address the issue during manufacturing, but biomanufacturers still desire
simple, cost-effective methods to control aggregation.27–29
One segment of the biopharmaceutical manufacturing process that is a candidate
for controlling aggregation is purification during the drug substance phase. Once
the cell culture and harvest steps have been completed, the process fluid containing
the proteins is pumped through a series of chromatography columns and filters for
purification primarily by separation. The first column in the purification process
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is generally a protein A, or capture, chromatography column. The purpose of this
column is to induce binding of the therapeutic protein with the column resin, allowing
much of the remaining material from upstream to pass through the column. However,
capture chromatography does not appreciably reduce aggregation, since the column
resin is designed to bind with an active site on the protein, even if that active site is
on a protein that has aggregated with others. Therefore, the ideal purification step
for removing aggregation is the next ionic exchange (IEX) column after the capture
operation.
Typically, the nature of IEX chromatographic purification in biomanufacturing
is such that the eluate, or output, from a given column is not of a constant purity
during the course of operation. The proteins in the eluate can exit the column in
varying concentrations over time, so an online measure of protein concentration, such
as UV absorbance, has traditionally been used to determine when to stop elution to
collect the column pool. In certain instances, such as when the therapeutic protein
has very little propensity to aggregate, UV absorbance is sufficient for monitoring
chromatography since the level of aggregation remains negligible during the opera-
tion. However, it has been shown that pooling by UV is suboptimal whenever the
chromatography operation is being employed as a means to separate the product from
impurities with similar UV absorbance characteristics like aggregates. This is because
UV absorbance is a measure of concentration, but alone it does not directly measure
the level of aggregated proteins.24
Online UV spectroscopy can measure protein concentration because aromatic
amino acids—primarily tyrosine and tryptophan—absorb ultraviolet radiation. There-
fore, the amount of absorbance of UV radiation in a sample volume can be an indicator
of the number of amino acids in that volume, which provides a method to measure
protein concentration. On the other hand, since UV only distinguishes the number
of amino acids in a given unit volume, it does not provide a measure of whether the
sample is composed of monomer proteins or aggregated proteins. To illustrate, x pro-
tein monomers in a sample would absorb basically the same amount of UV radiation
as x/2 protein dimers because the same amount of amino acids are present in each. As
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a result, UV absorbance is insufficient to determine the level of protein aggregation in
a sample. Figure 3-5 shows an illustration of a traditional chromatography analysis
and control system using UV spectroscopy.
Figure 3-5: Illustration of chromatography analysis and control using UV
In this case study, we present a novel PAT system for analyzing and controlling
chromatography during biopharmaceutical manufacturing. Specifically, the system
focuses on chromatography unit operations that target the reduction of high molecular
weight species (HMWS), such as the first IEX column. HMWS is a measure of
the presence of particles with a molecular weight higher than the protein monomer,
which includes protein aggregates. In addition, after a chromatography operation,
we assume that the only high molecular weight species in the process stream are
aggregated proteins, which is generally the case because capture chromatography
will tend to retain only proteins—both aggregated and not aggregated—and will
release any other high molecular weight particles. While the complete elimination of
HMWS might be desirable, it is not practical because there is a trade-off between
the amount of pure protein produced and the reduction of HMWS. We will see that
since aggregated species begin entering the stream in small quantities early in the
chromatography operation, complete elimination of HMWS would require a significant
decrease in the yield of protein product. Therefore, we will consider the PAT system
from the standpoint of controlling to a desired level of HMWS that is sufficiently low.
The opportunity for a novel PAT system was identified from improvements in an
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oﬄine analytical technology, static light scattering, in addition to improved tech-
nology in a class of industrial optical detectors, UV spectrophotometers. High-
throughput, continuous methods for analyzing molecular weight of proteins in a labo-
ratory chromatography column have been improving over the past several years. Since
UV absorbance is correlated with protein concentration,30 and since UV spectropho-
tometers are readily available, UV-oriented chromatography analysis and control has
commonly been used to aid in meeting objectives such as reduced HMWS. However,
instantaneous protein concentration in the process is not necessarily indicative of the
amount of HMWS present in the chromatography pool. For this reason, a method for
control that relies on a more direct method of measuring HMWS—or alternatively,
protein purity—is desirable.
The proposed method for measuring the level of HMWS is assessing average molec-
ular weight, which is commonly measured by combining UV spectroscopy with static
light scattering on the outlet of a high pressure liquid chromatography (HPLC) col-
umn. This method is commonly used in laboratories, but the relationship between
HMWS and average molecular weight depends on the composition of the sample,
which will be discussed at length. The advent of UV spectrophotometers and static
light scattering analyzers that can continuously measure protein characteristics in a
flowing process stream, rather than being constrained to batch samples, has both
increased the number of experiments that can be performed in a given period of time
and increased the ability to measure how average molecular weight changes during
the course of a chromatography elution. However, the instrumentation and analytical
systems for SEC elutions are optimized for protein concentrations and process flow
rates typical of a laboratory elution, which is on the order of 1 mL/min (flow rate)
and 0.1 to 1 mg/mL (milligrams of protein per milliliter of solution). On the other
hand, large-scale biomanufacturing purification process streams have flow rates in
excess of 1 L/min and can see much higher concentrations. Therefore, these methods
will not scale to the much higher flow rates and concentrations seen in commercial
manufacturing without requiring the diversion of a dedicated mL/min flow from the
higher flow rate process stream.
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For this reason, attempts have been made to assess protein purity on-line in com-
mercial manufacturing, particularly by increasing the throughput of a laboratory
HPLC system and diverting a small flow rate stream to it.25 An illustration of this
setup is shown in Figure 3-6. While this approach is a valid way to assess purity
of a protein stream on-line, it has the disadvantages of being a relatively complex
system, requires a diverted flow stream for analysis, and is subject to residence time
limitations due to holdup in the HPLC equipment. The primary advantages of the
system are its accuracy, sensitivity, and similarity to traditional laboratory assays
used to determine protein purity.
Figure 3-6: Illustration of chromatography analysis and control for aggregation
using HPLC system
The novel PAT system proposed here takes a new approach by combining charac-
teristics of each method. First, it employs UV as a measure of concentration, then it
employs light scattering as a measure of particle size. Light scattering, when combined
with UV detection, can provide an accurate measure of average molecular weight. In
fact, this approach is not so different from on-line HPLC methods, since those meth-
ods often employ sensitive optical detection based on UV or light scattering principles
to calculate purity. In a way, the novelty of this approach is the elimination of the
additional HPLC columns, elimination of the pumping system, and transition of the
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analyzers to the main process stream.
A key rationale behind this approach is that commercial-scale chromatography
columns optimized for the reduction of high molecular weight species (HMWS) will
clarify the process stream sufficiently for the average molecular weight of the pro-
teins to be assessed without the need for an additional, analytical chromatographic
separation. Additionally, light scattering and UV absorbance devices have reached
sufficient size and throughput to handle the larger flows required for commercial man-
ufacturing. This increased throughput does not necessarily increase the measurement
volume, but it does allow for the measured volume (presumably a representative sam-
ple of the process) to be analyzed quickly and efficiently. For these optical devices,
a key development that enabled their use in manufacturing was flow cells with short
enough path lengths to measure undiluted process flow streams. Therefore, the pro-
posed PAT system is one that employs a large-scale light scattering device and UV
device.
The novel setup is shown in Figure 3-7. In order to further substantiate the
concept, the large-scale system was also demonstrated using a laboratory scale light
scattering device on a diverted low flow rate stream for analysis. Traditional manu-
facturing chromatography analysis and control methods also employ human or auto-
mated operators that monitor the output of a UV detector in order to stop elution
before a predetermined level of concentration is reach. Since concentration in this
case is taken to be an indirect indication of purity, this indicates that there is a
tradeoff that can be optimized between product purity and step yield. The opti-
mal elution can then be achieved by improving the PAT system used to analyze and
control chromatography. For this reason, the proposed PAT system will also require
modifications to the automation and control process to maximize benefits. These
modifications include changes in human operator processes and algorithms used to
control the chromatography operation. A core component of these changes is devising
a suitable mathematical equation to calculate the average molecular weight online.
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Figure 3-7: Illustration of chromatography analysis and control for aggregation
using novel PAT system
3.4.2 Theory
The theoretical basis for the proposed PAT method of measuring average molecular
weight online is that protein concentration can be measured using UV absorbance30
and that the process stream at the outlet of the chromatography column can be
modeled as a solution of particles that scatter light akin to other particles that are
much smaller than the wavelength of the light that they are scattering. Dollinger et
al. demonstrate that such a protein solution can be modeled using the Rayleigh-Gans-
Debye approximation of the Mie solution to Maxwell’s equations for light scattering
as shown in Equation 3.1.
Kρ
R(θ)
=
1
MP (θ)
+ 2A2ρ+O(ρ
2) + ... (3.1)
K is an optical constant of the solution, ρ is the solute (protein) mass concentra-
tion, R(θ) is the average excess Rayleigh ratio, P (θ) is a scattering factor related to
size and shape, and M is the average molecular weight.
This model is for the process stream, or protein solution, at an instantaneous
point in time. It can also be thought of as an infinitesimally thick cross-section of
the process fluid that is measured by the analyzers. The approximation is expanded
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by powers of ρ, so A2 represents the second virial coefficient in the expansion. We
will presume at this point that orders of ρ greater than or equal to 2 are negligible
for ease of computation. It can then be assumed that light scattering is independent
of size and shape, so P (θ) approaches 1 because the protein is not sufficiently large
compared to the wavelength of light emitted.
While the literature can be consulted for additional information on calculating, K
and R(θ), it is worth recognizing that K contains constants related to the inherent
properties of the light, solvent, and solute, while R(θ) can be explained as containing
the variables for intensity of detected scattered light at a given angle relative to a
baseline background scattered light intensity. We will also assume that the refractive
index of the solvent, contained in K, remains constant.
Therefore, as Dollinger and his coauthors indicate, the equation to calculate av-
erage molecular weight can be reduced to Equation 3.2 based on the assumptions
given. IS is the output of a light scattering detector placed at 90
◦ from the light
source, A is the absorptivity of the protein, and UV is the absorbance of UV radia-
tion as measured by the analyzer. The term for ρ from Equation 3.1 converts to UV
and A because concentration is measured using UV spectroscopy and Beer-Lambert’s
law is assumed. The term for R(θ) converts to IS if a single light scattering detector
is placed at an angle from the light source. k′′ is an instrument and angle-dependent
constant, and A and k′′ can also be combined into a protein and instrumentation
dependent constant.
M =
ISA
k′′UV
(3.2)
In short, the measurements of interest for determining average molecular weight
are the absorbance of ultraviolet light—normally with a wavelength of 280–300 nm—
by the process stream, and the intensity of scattered light—normally with a wave-
length of 500–700 nm) at a 90 degree angle. The scattered light wavelength of 500–700
nm is desirable because the scattering of light by the proteins begins to deviate from
the model as the wavelength deviates from this range. Furthermore, Equation 3.2
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can be used independently for any angle of light scattering detection provided the
constants are adjusted accordingly.31
Several assumptions are made in this simplification, namely that the protein of
interest is very small compared to the wavelength of light scattered (i.e. 500–700nm).
Since most commercial therapeutic proteins are monoclonal antibodies with a radius
of less than 10 nm, and other therapeutic proteins are generally smaller than mon-
oclonal antibodies, then this assumption holds for our purposes. The equation also
assumes that the optical detectors are calibrated correctly and that the specific refrac-
tive index increment of the solute and absorptivity of the solution remain constant.
Furthermore, this also assumes that the concentration is not so high that higher order
terms of ρ impact the calculation.
These assumptions will serve for the purposes of demonstrating this novel system,
and the consequences of these assumptions will be discussed in more detail. In this
way, we see that the average molecular weight of proteins in a process stream is related
to the amount of light scattered (as measured by the light scattering detector at a
given angle) and the concentration of proteins in the solution (as measured by a UV
spectrophotometer).
3.4.3 Materials and Methods
Four experimental runs were conducted on large-scale (30 cm diameter) IEX columns
in a pilot plant facility. The flow rate for runs 2, 3, and 4, was held constant at a flow
rate of approximately 2 L/min in the 3/4” outlet line of the column. The flow rate
for run 1 was 0.8 L/min. For online UV detection, an Optek® AF46 was used, and
a customized Optek turbidimeter was employed for online light scattering detection
(with detectors at 11◦ and 90◦). For laboratory-scale replication of the data, a Wyatt
DAWN HELEOS® II and an Agilent 1200 series UV-Vis detector were used. The
customized Optek turbidimeter was placed directly on the 2 L/min process stream,
while the Wyatt DAWN HELEOS® II was limited to a flow rate of 2 mL/min. The
column packing and size was optimized to the protein of interest.
Laboratory assays of percent purity (and percent HMWS) were conducted by
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SE-HPLC according to methods approved for use in commercial biopharmaceutical
production. All instrumentation for the large-scale experiments was connected to a
digital process automation system to test and prove control criteria and algorithms.
The run charts displayed in the figures were based on online data sampled by the
process automation system every 0.5 seconds. The one exception to this is the oﬄine
percent HMWS measurement, which was based off of samples extracted from the
process once every 3 minutes. In order to facilitate visualization, the online data (UV ,
IS, and M) in the figures was resampled at the same 3 minute intervals. However,
because the online data was sampled at time intervals significantly shorter than the
scales presented, it is shown to be continuous.
Samples were extracted from the process at regular intervals to verify the percent-
age of HMWS in the process at a given elution time. These samples were taken by
initiating a pump that diverted a small amount of the process to sample vials in a
rotating fraction collector until they were filled to approximately 3 mL. At 1 mL/min,
the 3 mL fill would take 3 minutes, and then the next sample vial was automatically
rotated into place. We assumed that the % HMWS measurement of each sample was
representative of the process at the midpoint of collection time. For calculations of
% HMWS in the pool, we verified the volume of each sample and then calculated the
accumulated % HMWS up to a given sample from the time of initiating the gradient
elution by using the accumulation of individual measurements.
All experimental runs were performed with the same monoclonal antibody, but
the antibodies for each run were generated by separate bioreactor purification runs.
For the second experimental run, the cell culture conditions were sufficiently different
to significantly change the HMWS profile during the run, so it is not included in the
results section. Tabulated data from the experiments is included in the Supplemental
Information section of Appendix A.
3.4.4 Results
The goal of the novel PAT system presented here is to offer a new approach to analysis
and control of large-scale chromatography specifically with the intent of reducing the
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level of aggregated protein species in biopharmaceutical manufacturing. The system
is based on employing a UV detector and a light scattering detector near the outlet
of the manufacturing column and using the analyzer outputs to monitor the average
molecular weight of the process stream at a given point in time. This, as will be
discussed, can be used to control the level of high molecular weight species (HMWS).
The system is most notable for its speed and simplicity.
A system capable of online control must be able to output reliable online data.
To illustrate a practical application of Equation 3.2, an illustration of the analyzer
output and average molecular weight calculation of a typical experiment is given in
Figure 3-8. For this and all subsequent figures, UV represents absorbance at 300 nm
as a fraction of maximum absorbance recorded over the course of the experiment,
in other words UV = UV
UV,maximum
. Similarly, light scattering output values will be
scattered light intensity at 90◦ as a fraction of its maximum, or IS = ISIS ,maximum . The
initial units of UV as output by the detector were OD (optical density), and the initial
IS units were in volts. Finally, protein molecular weight will be given as the fraction
by which it exceeds the baseline monomer molecular weight, or M = M
M,monomer
. The
average molecular weight of therapeutic proteins tends to be in the range of 50–200
kilodaltons (kDa). Since the redefinition of the variables, UV , IS, and M , results in
their becoming relative values, they will now also be unitless quantities.
As illustrated in Figure 3-8, the monomer protein elutes first, so the average molec-
ular weight of the proteins in the process stream at any point in time is constant until
a transition point when the molecular weight of the process stream begins to increase
(in Figure 3-8, this occurs at about 1 hour). While the experiments published here
were all performed with a single type of protein, other parallel experiments with other
types of proteins indicated similar trends. This helps confirm the assumption that
only pure monomer elutes early and larger species elute later. Correspondingly, UV
and IS are equal as long as the average molecular weight of the proteins equals the
average molecular weight of the monomer. UV and IS diverge when the average
molecular weight of the proteins exceeds that of monomers. Therefore, by measur-
ing UV absorbance and light scattering, a real-time measurement of instantaneous
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Figure 3-8: Example of overlaid UV , IS, and M run charts during an experimental
run
average molecular weight can be calculated.
This approach can be applied when the maximum UV absorbance and maximum
scattered light properties of the elution are both known and unknown. If they are
known, then k′′ and A from Equation 3.2 can be calculated, and a run chart of the
elution would look similar to Figure 3-8. However, in some cases, especially during
process development, the expected absorbance and scattered light values are not
known with much certainty, if at all. Furthermore, issues with instrument calibration
and drift may cause changes in the measured maximum values from run to run. Using
arbitrary k′′ and A values would cause M not to be constant during monomer elution
and the UV and IS values would not match. One way that this problem can be
addressed is by incorporating an algorithm for detecting the maximum UV and IS
values in real-time, and once the maximums are detected, immediately inputting the
values into the molecular weight calculation at the time of detection. This would
ensure that after the maximum values are detected, all future calculations during
the run would be accurate. This is particularly helpful because the transition point
when aggregated species begin eluting is a sufficient amount of time later than when
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maximum UV and IS values are recorded.
Flow rate effects and time alignment of analyzer outputs can be other important
issues to consider. In systems similar to Figure 3-6, the low flow rate stream diverted
to the analytical equipment can present an issue because the time it takes for a given
unit of the process stream to be diverted and analyzed can delay the ability of an
operator to take action. Similarly, using a laboratory-scale light scattering detector
in an equivalent setup could cause a noticeable delay between the UV detection of
a given unit of process stream flow and the corresponding scattered light detection
due to dead volume in the line and the pump required to deliver the stream to the
analyzer.
Therefore, this PAT system in concept presents a novel method for controlling
pooling during chromatography because it allows for the elution to be stopped—
and the batch to be collected—at a point in time that corresponds with a desired
instantaneous average molecular weight of the process proteins. Normally, though,
the percentage of high molecular weight species (HMWS) by mass in the collected
pool is desired, but this cannot be calculated without knowing the composition and
types of HMWS present in the process stream—be they dimers, trimers, or larger
aggregates. Conversely, if the composition profile as a function of time is known,
then the % HMWS in the pool can be calculated. If we assume, for the moment,
that any increase in average molecular weight is due only to the introduction of
dimer aggregates, or two bound monomers, then the instantaneous average molecular
weight of the proteins will change linearly with the percent HMWS in the collected
pool. As shown in Figure 3-9 for the same experimental run, M appears to correlate
linearly with the percent HMWS in the pool over the time period shown, suggesting
that for this time range the process stream is composed almost only of monomers and
dimer aggregates. The HMWS value in the figure was calculated by using a validated
oﬄine method for such a measurement. As displayed, the detectable dimer aggregates
begin entering the stream at approximately the 1 hour point. However as indicated
in the figure, the novel PAT system is not quite as sensitive to low levels of aggregate
species as analysis performed oﬄine in a laboratory.
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This linear relationship holds because the % HMWS in the pool is now directly
proportional to the mass fraction of dimer in the pool at a given time, which is directly
proportional to the instantaneous average molecular weight. At some point in the elu-
tion, the process stream contains larger aggregate proteins, so the linear relationship
no longer holds. But in most cases, including cases reviewed for other therapeu-
tic proteins, the optimal point for stopping elution and collecting the pool is before
these much larger aggregates begin to appear. This is due to the optimum collection
point being one that minimizes high molecular weight species without compromising
process yield, so we will not examine the elution region containing detectable larger-
than-dimer species. Rather, we will assume that elution is stopped sometime before
a level of 3% HMWS is reached for this protein (i.e. about 1.5 hours in Figures 3-8
and 3-9).
Accordingly, Figure 3-10 shows the correlation between % HMWS in the pool and
M , where the former is plotted as a function of the latter. This data was gathered
from 3 experimental runs under similar conditions. These data were also replicated
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Figure 3-10: % HMWS in pool as a function of M - error bars represent one standard
deviation around the mean
smaller scales, but this replication is not shown here. However, the results from those
experiments were similar.
We see that M does not exceed 1 until the % HMWS in the collected pool exceeds
0.5%. This suggests an approximate detection limit of the current method as pre-
sented. For the % HMWS values greater than 0.5% (above the presumed detection
limit), the linear R2 for the data is 0.983. This lends credibility to the notion that
for this specific application and range of % HMWS in the pool, M can be used to
calculate the accumulated high molecular weight species in the pool because the sys-
tem behaves only as if the process is composed of monomer protein and, later in the
elution, dimer aggregates. Data reviewed at values greater than 3% HMWS in the
pool indicate that, as expected, this correlation becomes nonlinear, indicating trimer
and higher order aggregates begin eluting at approximately this time.
While 2 L/min can be considered manufacturing scale, some large biomanufactur-
ing processes can exceed that flow rate. For processes that operate at an even larger
scale, a few assumptions would need to be revisited and tested to ensure that this
novel PAT system continues to provide an effective means of analyzing and control-
ling chromatography. First, the sensitivity and reliability of the detectors and light
emission source are important aspects of optical measurements, and improvements in
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these areas may improve the correlation of the molecular weight calculation and the
% HMWS in the pool. Second, while the general method described will hold true
for a variety of manufacturing operations, different column resins, pumps and other
process equipment changes will likely have some impact on the data. Third, while
the concentration used in these experiments is very high by most current industrial
standards, additional increases in concentration will require revisiting the use of Beer-
Lambert’s law and a second order Rayleigh-Gans-Debye approximation to calculate
the instantaneous molecular weight. Fourth, as previously mentioned, there are other
methods for assessing process stream purity, and judgment is required when assessing
whether the benefits of speed and simplicity outweigh the alternatives of precision and
sensitivity. Finally, while the run to run variability appears to be low, more research
is needed in establishing a method acceptable both to the bioprocessor, patient, and
regulatory agencies.
In spite of these qualifications and areas where variability can be introduced, it
bears restating that this method is useful because of its simplicity and speed. In
addition, what seemed like rather significant assumptions in theory turned out to
have a very low impact on the actual results. For this reason, scaling up flow rate
and concentration could have minimal impact on the results presented here.
3.4.5 Limitations
The novel PAT system presented in this thesis does have some limitations. First,
as previously mentioned, it is currently applicable only to chromatography systems
where large particle reduction of dimer size or greater is an important objective of
the targeted chromatography step. Because the system is based on principles of light
scattering by particles, a process eluate that contains large amounts of scattering par-
ticles, which are not proteins, will scatter excess light and deviate from the proposed
model. Therefore, this system assumes that the manufacturing chromatography col-
umn and any prior processing steps clarify the stream sufficiently to avoid such a
scenario. Similarly, other particles may interfere with the use of a UV-based analysis
and control system as well. The light scattering detection device, or turbidimeter,
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used for our experiments was the joint development effort of the supplier and our
team, so it is not yet widely available.
Second, there was an experimental run that yielded outlying data that was not
presented with the results. In short, for that particular run the level of aggregated
species was significantly lower than the relatively consistent levels displayed in the re-
sults. While the precise source is under investigation, evidence indicates that changes
made to processing conditions upstream of the chromatography operation resulted
in various downstream effects, including lower aggregation levels. Since this was a
developmental run, such changes and excursions are not unusual. However, since the
changes were significantly different from the other runs presented, the data was not
included in our results. Before therapeutic proteins are produced commercially for
patients, the biopharmaceutical manufacturing process is designed and engineered so
that the risk of unexpected changes is minimized. This scenario was instructive as a
means for testing the novel PAT system’s sensitivity to excursions and process upsets.
Finally, this system has only been tested on a single chromatography step targeting
the reduction of HMWS in the purification phase of drug substance manufacturing.
As discussed in Chapter 2, biopharmaceuticals are generally less stable than other
therapeutics, and this low stability extends to aggregation. Under certain conditions,
including those optimized for long-term storage, proteins can preferentially aggregate
over time depending on their particular characteristics. Therefore, any efforts to re-
duce HMWS during drug substance manufacturing may be negated by aggregation
occurring later in the manufacturing and supply chain. Since biopharmaceutical com-
panies keep relatively high inventories of product—and thus high product residence
times in the value chain, it is important to realize that this novel PAT system would
be just one component of a total aggregation control system.
In spite of these limitations, the novel PAT system is a beneficial addition to the
analysis and control toolkit of both widely-used and recently developed chromatogra-
phy analysis and control systems. In an effort to directly compare various aspects of
the novel system against other systems, Table 3.2 has been included to show the ad-
vantages and disadvantages of each. While developing suitable analytical equipment
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Description Advantages Disadvantages
Novel system (UV
and light scattering)
Rapid analysis Assumes only monomer
and dimer HMWS
Simple system
Directly measures M
Relatively inexpensive
Online UV
(traditional)
Rapid analysis No HMWS analysis
Simple system
Inexpensive
Online HPLC Most sensitive to HMWS Slower analysis time
Analysis independent of
composition
Complex system
Relatively expensive
Table 3.2: Advantages and disadvantages of novel PAT system relative to similar
systems
and hardware is an important part of implementing a PAT system, careful attention
must also be paid to developing the software algorithms, control system, and oper-
ating procedures as well. In reality, many biopharmaceutical manufacturing facilities
use commercially available analysis and control systems customized to the extent that
the vendor and manufacturer can agree upon. Furthermore, constraints on the num-
ber and skill level of operating personnel must also be considered. Finally, the entire
PAT system must be able to bear the rigors of long-term, high-volume manufacturing
while reliably controlling a process that delivers a safe and efficacious product to the
patient, ensures the safety of the operating personnel, and minimizes the impact on
the environment.
Wiring, input/output (I/O) hardware, and control scheme programming are im-
portant aspects of any PAT system, but an in-depth discussion will not be given
here. Rather, we will focus on a few key considerations for PAT systems in biophar-
maceutical manufacturing facilities. As discussed in Chapter 1, the recently issued
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PAT guidance has galvanized an effort that is being more openly embraced within
the biomanufacturing community. While many unit processes and operations, espe-
cially bioreactors, have made significant advances with PAT, the use of PAT on a
manufacturing facility level has not been standardized within the industry. For this
reason, different process analysis and control systems have varying degrees of “plug
and play” characteristics, or the ability to be easily integrated into biopharmaceutical
operations.
Because of the complexity of implementing new hardware, software, and control
systems, the installation of new PAT systems must involve a review of what data is
being transmitted from each analyzer and how that data should be used to measure
the attribute of interest. For example, in the novel PAT system presented, both a
UV spectrophotometer and light scattering analyzer are required to assess different
characteristics of the process stream, which in turn, are synthesized to calculate
average molecular weight. However, the biopharmaceutical manufacturer often has a
choice as to whether they combine data and make calculations within the distributed
control system (DCS) itself, or whether they do so in a separate processing device
prior to sending the final data stream to the DCS for control purposes.
In existing facilities, the decision will be strongly influenced by the capabilities
of the facility and personnel. However, in a new facility, there is often flexibility to
choose the optimal solution based on the PAT evaluation criteria outlined in sec-
tion 3.3. In the case of this PAT system, after interviews with various operations and
automation experts, we resolved that the optimal scenario was to send the UV and
light scattering data signals to the DCS system and use the DCS to make the molec-
ular weight calculation. The simplified equation for calculating M greatly facilitates
this application, and there were other applications where the separated signal outputs
from the UV and light scattering analyzer could be useful (i.e. calculating total mass
of protein processed or process stream turbidity). In any case, the average molecular
weight data transmitted within the DCS system can then be used to control a pump
or valves as necessary. Alternatively, a human operator actively monitor the relevant
output with complementary operating procedures to facilitate good manufacturing
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judgment.
The degree to which a PAT system should be automated is also an important
consideration. Automation, when carefully planned and implemented, can enhance
the quality of an operation, but there is often a tradeoff between the complexity, or
risk, of an automated system and the benefit from automation. For example, in the
case of the novel PAT system, if an operator is already closely monitoring a small
set of other process attributes during the chromatography elution, then automating
one pump or valve may be unnecessary and add no additional value. However, if a
required sample preparation and analysis is sufficiently frequent and time consuming,
then automation may help reduce the burden and stress on operators.
Operating procedures are also an extremely important aspect of the PAT system.
Procedures should be developed in collaboration with the hardware, software, con-
trols, and automation disciplines in order to ensure effective operation of the facility
over the long-term. Ideally, procedures are sufficiently detailed to operate the facility,
but not so detailed as to be cumbersome. Effective procedures and proper process
discipline will ensure that the plant is operated effectively and safely.
The need for development of effective experimentation coincides with another
important need to develop personnel capable of using sound judgment when making
decisions based on PAT-derived data. The increase in the number of PAT systems
in biopharmaceutical manufacturing facilities will require management, operational,
and technical staff to become more adept at working with an evolving set of process
protocols. These personnel will also need to ensure that PAT systems developed in
the future are not only technologically advanced, but that they can be effectively
operated in such a way that optimally manages product risk.
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3.5 Designing PAT for risk management and for
the end user
In many situations, biopharmaceutical manufacturers have operated plants that have
two distinct areas and organizations, both of which are critical to the effective and safe
manufacture of biopharmaceuticals: the laboratory and the manufacturing floor. In
some cases, even different laboratories and manufacturing areas can develop distinct
cultures, but for this discussion we will primarily consider the difference between labs
and operating areas. As indicated in Chapter 1, the laboratory and manufacturing
floor are the two primary dimensions from which PAT system concepts should be
generated, and a general understanding of how PAT can unify these areas and the
challenges involved is merited.
For laboratory-based tasks, the analytical systems are generally designed and en-
gineered to measure a specific attribute or attributes with a high sensitivity and accu-
racy. For process-oriented technologies, the emphasis tends to shift toward robustness
to a manufacturing environment, reliability, and rapid analysis. When developing a
PAT system, it is crucial that individuals with expertise in both areas are involved in
development, because the ideal PAT system encompasses characteristics from both ar-
eas. Furthermore, a focus on the needs of the intended PAT application is paramount.
Understanding how frequently the system should measure an attribute, how robust
the hardware needs to be, who will be responsible for operating and maintaining the
system, and how it interfaces with the facility control system will help determine the
optimal PAT system design. A methodical approach of this nature will help minimize
suboptimal outcomes where development emphasizes a narrow set of criteria that
results in an unusable PAT solution.
The novel system presented here was first evaluated in a laboratory before at-
tempts were made to scale up the system for large-scale operations. It is important
to note that, in many ways, the laboratory-scale system and large-scale system are
similar in concept and purpose, but a simple proportional increase of the labora-
tory system to manufacturing scale would have rendered the system unusable. For
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this reason, it is critical that the needs of the end user be considered at every stage
of the development process. For example, the light scattering analyzer used at the
laboratory scale was optimized for use with laboratory hardware, control systems,
and flow rates. Using the same device in manufacturing would have constrained the
system to a diverted flow stream and reduced the benefit it provides. Therefore, we
researched and developed the manufacturing-scale turbidimeter that had the capabil-
ities we needed, and it was optimized for the needs of a large-scale, biopharmaceutical
manufacturing environment.
Conversely, this approach may jeopardize the very results that are obtained at
small scales, so rapid, cost-effective experimentation must be employed to optimize
key attributes of the system as it moves through development. For example, light
scattering analyzers often measure scattered light at multiple angles to improve the
accuracy of the molecular weight calculation. However, in the case of the PAT system
presented here, the high concentration of protein in the process stream relative to
concentrations typically seen by light scattering analyzers helped determine the ideal
number of measuring angles that would most effectively determine average molecular
weight. By designing and executing a series of simple, fast experiments, we were able
to reach an informed decision regarding the optimal state of this attribute .
As PAT systems are deployed in biopharmaceutical manufacturing operations, ad-
ditional questions remain from an organizational perspective regarding how to deploy
personnel within the manufacturing, quality, and technical subdivisions of the op-
erational organization structure. While a variety of different organizational regimes
are in place throughout industry, a key trade-off that deserves discussion is balancing
the role of the quality organization as an auditor, the role of manufacturing as the
efficient producer, and the role of research and engineering as the technology devel-
oper. Some organizational separation between the groups facilitates the development
of functional expertise in specific areas and helps employees feel a sense of progression
as they acquire and improve capabilities. However, excessive division, or “siloing,”
can result in restricted flows of information that are necessary for the organization to
effectively achieve its goals. Notably, a quality organization is required by regulatory
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organizations, so the degree of integration must adhere to these regulations. As far as
PAT systems are concerned, it is imperative that quality, manufacturing, and techni-
cal personnel interact in a way that ensures that feedback, learning, and continuous
improvement are commonplace.
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Chapter 4
Areas of further research and
development
In Chapter 2 we reviewed literature regarding process analytical technologies that,
for the most part, are either currently in use or commercially available. Many of
these technologies are continually being refined and have great potential for bringing
significant benefits to biopharmaceutical manufacturing in the future. There are also
many technologies that have been developed in recent years, have been identified as
potential PAT applications, or could become key components of future biopharmaceu-
tical manufacturing PAT systems. Because most of these technologies are recent, the
horizon for implementation as PAT tools may be a few years away, but the purpose
of this investigation is to shed light on some promising opportunities.
4.1 Advanced optical technology
An area of ongoing development for future PAT systems is optical analysis. Many
optical technologies have been used in biopharmaceutical operations in some form or
another for years, but generally they have not been widely employed as PAT systems,
with the exception of UV spectroscopy. The novel PAT method described in Chapter
3 is one example of an advanced optical technology, because even relatively simple
systems employing UV and light scattering detectors have not been previously used
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to analyze and control large-scale chromatography.
The literature describing optical systems is robust, and there are several key areas
of development regarding the use of optical technologies in biomanufacturing. First,
PAT systems employing Near Infrared Spectroscopy (NIRS) are a promising oppor-
tunity for improving biopharmaceutical manufacturing. Measuring absorbance in the
near infrared region of the electromagnetic spectrum is challenging in a manufactur-
ing environment, especially for online applications. Scarff, et al. note that sufficient
progress has been made both in analytical and computational technology to ensure
that NIRS could be used in the future as a reliable, online analytical system. While
the signal from a NIRS system can be more difficult to resolve into meaningful data
than, a UV absorbance signal, for example, measuring absorbance of near-infrared
radiation can be a very effective method for rapidly assessing the amount of nutrients
and wastes in a cell culture.32
In addition to NIRS, Raman spectroscopy is a promising advanced optical tech-
nology that is a candidate for evaluating the multiple components contained in cell
culture media. As indicated by Li and coauthors Raman spectroscopy systems have
a unique advantage over other technologies because water is a weak Raman scatter-
ing compound. Also, Raman spectroscopy methods generally require no special or
lengthy sample preparation regimes. The system developed by the authors demon-
strates the application of Raman spectroscopy to analyzing cell culture media used
in CHO-based bioreactors, which is another area where PAT systems could satisfy a
biopharmaceutical manufacturing need.33
Clearly, advanced optical technologies offer promising advantages that are well-
suited to PAT systems, such as rapid analysis and control of multiple components
in a process. While the rate of adoption of advanced optical technologies remains
low at manufacturing scales, recent improvements in signal processing, analysis, and
computation promise to improve the prospects of such devices for inclusion in bio-
pharmaceutical manufacturing facilities.
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4.2 Microscale and nanoscale devices
A microscale device employs the space-saving attributes characteristic of microchips in
order to fit all of the components of an integrated system in a miniaturized footprint.
At times, microscale devices contain all of the requisite materials required to perform
one or several laboratory assays (also referred to as “lab-on-a-chip”). While there
is some overlap between the categories of microscale devices and optical analytical
systems (i.e. hybrid microscale optical devices), the purpose of this section is to focus
on PAT developments within the microscale category. Such devices have existed for
decades, but many significant developments have recently been made in the area
pertaining to biopharmaceutical manufacturing and biological analysis.
Love offers his perspective on bioanalytical technologies and how—when properly
designed—they can improve analysis for biological applications. He describes the
current state of bioanalytical microchips and their focus on scaling down traditional
analytical assays, and goes on to suggest that microchips that can perform a variety
of tests, or “unit operations”, on a single sample of cells will vastly increase the
knowledge acquired per assay∗. He further discusses the importance of being able to
scale analytical technologies to handle ever increasing sample sizes. This is a critical
barrier to overcome because many concepts are limited in their ability to scale, which
impedes the progress of the use of microchips and microfluidic devices within PAT
systems. Furthermore, Love gives an example of a scalable, multi-assay chip used to
a robust analytical profile of single cells.34 Love’s perspective sets the stage for our
investigation of micro and nanoscale devices. As this field of development grows, it
will become increasingly necessary for sound engineering principles to be applied so
that discrete analytical tests focused on single biological attributes can be effectively
combined within a multi-assay device that ensures optimal knowledge acquired per
sample.
One growing field of research that is a prime candidate for multifunctional mi-
crochips is glycobiology. In particular, increasing the speed and throughput of gly-
∗In Chapter 3, acquisition of knowledge is highlighted as one key component for evaluating PAT
opportunities.
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can assays has gained attention due to the fact that the glycosylation—or lack of
glycosylation—of therapeutic proteins has a significant impact on their therapeutic
function. Reuel and his coauthors review the burgeoning field of rapid, nanoscale,
glycan profiling devices. One of their primary findings is that most of these devices
require no labeling or additional steps to detach the glycan from its host protein.
Traditional glycan analysis methods such as mass spectrometry, chromatography,
and capillary electrophoresis often require such a cleaving step before performing the
actual glycosylation assay. Microchips, on the other hand, can provide rapid genera-
tion of glycosylation profiles of a protein sample with minimal preparative work. The
device reviewed employ various modes of detection such as microscale cantilevers,
quartz crystals, and fluorescing carbon nanotubes as methods of determining the
glycosylation-related attributes of therapeutic proteins.35
Clearly, rapid, high-throughput analytical methods such as these glycosylation
profilers are promising candidates for inclusion in an integrated, analytical microde-
vice that could be used as a future PAT tool for biopharmaceutical manufacturing.
One could envision such devices interfacing with bioreactors during protein produc-
tion to perform rapid assays of cells and proteins which could then determine whether
process parameters are appropriate to produce the desired products.
The microscale technologies discussed so far have often been developed and op-
timized for analyzing the attributes of various aspects of a proteins, cells, or their
components. Many of these devices can also be adapted to use the same technological
principles to analyze and detect impurities in the biopharmaceutical manufacturing
process such as viruses, nucleic acids, and bacteria. In many ways, ensuring that
a manufactured therapeutic solution is free of potentially damaging impurities is at
least as important as ensuring that the protein and other desired product components
meet specifications. Controlling impurities is a critical factor in biopharmaceutical
manufacturing, but the topic has previously received little public attention because
contaminations can be a sensitive topic for companies to disclose. However, a signifi-
cant viral contamination at a Genzyme facility and the subsequent product rationing
that ensued highlighted the need to understand how impurities contribute to prod-
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uct risk.36 The technology used in the microscale devices described here could also
be used in the detection of impurities. In this way, an integrated microscale device
or devices could assist in the type of holistic monitoring of the biopharmaceutical
manufacturing process described in Chapter 2.
4.3 Technology from other industries and disci-
plines
We have previously mentioned that biopharmaceutical manufacturing is similar in
many ways to other process industries, including oil refining and fermenting yeast.
The list of similar industries could also include water purification and treatment, tra-
ditional pharmaceutical manufacturing, food processing, and chemical manufacturing.
Because individual industries emphasize development of technology at different rates
and in different areas, it remains imperative that biopharmaceutical manufacturers
and other participants in the biopharmaceutical value chain monitor and leverage
developments in other industries and disciplines.
Junker and Wang point out that many of the key developments that led to the
current biopharmaceutical PAT initiative came before widespread biopharmaceutical
manufacturing based on recombinant DNA-enabled cell lines. Other industries that
developed and enhanced the early versions of computer-controlled fermentation were
involved in the production of food proteins, enzymes, antibiotics, and organic acids,
among others.20 When new industries, such as biotechnology, are created, they of-
ten rely on previously developed technology to enable their operations. It is vital
that these industries avoid the trap of becoming too reliant on internally developed
technology at the expense of leveraged opportunities for improvement.
For example, our novel PAT system was the result of the sharing of information
across industries. The capabilities to modify the high-sensitivity turbidimeter used
in the novel PAT system described in Chapter 3 would not have been available had
our supplier not developed similar process analyzers for yeast fermentation. Although
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these process analyzers were not optimized for our application, the combination of
biopharmaceutical, process analysis, and yeast fermentation expertise enabled our
team to optimize critical device components such as materials, process connectivity,
control system connectivity, radiation source, detection methods, and data transmis-
sion. After sharing experience and expertise, we were able to engineer the PAT system
so that it would be an ideal solution for our targeted application.
In a similar way, biopharmaceutical manufacturing can benefit from—and con-
tribute to—interactions and knowledge sharing with other industries and disciplines.
Other opportunities to combine knowledge regarding process analytical technology
for disparate sources will continue to appear in the future. However, in order to take
advantage of these opportunities, the biopharmaceutical industry needs to ensure that
it employs people with a diverse set of skills and expertise. Knowing what types of
skills and abilities are ideal for the development and implementation of new technol-
ogy can be difficult, and our recommendations can provide some guidance on how
best to prepare an operational organization to incorporate PAT systems effectively.
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Chapter 5
Recommendations
We have detailed a framework to aid in identifying, evaluating, and implementing
PAT opportunities. In addition, we have described a novel PAT system that can
be used to analyze and control large-scale chromatography. The novel PAT system
clearly demonstrated that opportunities exist for valuable implementation of future
PAT systems, for which we will provide our recommendations. In light of these re-
sults, these recommendations align with five major categories: a simple PAT strategy
message, opportunity identification, system evaluation, chromatography analysis and
control, and areas for future research.
As discussed in Chapter 2, a critical factor to the success of any organizational
PAT deployment is starting with a simple message. For this reason, we recommend
that organizations communicate that PAT manages product risk throughout the phar-
maceutical manufacturing value chain through the innovative, effective acquisition and
application of data. The importance of clearly communicating new ideas or projects
throughout an organization is sometimes overlooked, and for this reason we encourage
PAT adopters to ensure that they invest the time and effort necessary to effectively
communicate the rationale behind PAT.
For opportunity identification, we recommend that a holistic, two-dimensional
approach such as that described in Chapter 3 be adopted. It is not sufficient to
simply examine discrete unit operations within a biopharmaceutical manufacturing
facility in an effort to identify areas for PAT improvement. The focus should be
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on actively synthesizing information from both laboratory assays and manufacturing
unit operations in order to find ways to improve the overall capability of integrated
facilities to manage product risk. While these opportunities may arise from individual
operations, many beneficial opportunities will result from combining operations into
continuous flow or augmenting process control by incorporating oﬄine assays into a
PAT system.
We further recommend that potential PAT systems be evaluated according to the
criteria of quality, cycle time, yield, process knowledge, and cost. By employing these
criteria, PAT systems can be effectively implemented in biopharmaceutical operations
and enhance the risk management capabilities of the facility. Process knowledge is
not always a commonly used criterion, but as we discussed in Chapter 4 the increased
yield of process knowledge per sample analyzed can greatly benefit biopharmaceutical
manufacturing.
We recommend the novel PAT system presented in Chapter 3 for analyzing and
controlling large-scale chromatography, specifically chromatography that targets the
reduction of high molecular weight species (HMWS). Using a light scattering analyzer
and UV spectrophotometer enables online analysis of average molecular weight in the
process stream, which correlates to the cumulative % HMWS processed (under cer-
tain conditions). While this may not be the ideal solution for every chromatography
step, it is especially advantageous given its simplicity, speed, and direct measure-
ment of average molecular weight as compared to alternative chromatography control
methods.
Finally, we recommend that further process analytical technology research fo-
cus on advanced optical technologies, microscale and nanoscale devices, and sharing
knowledge with other industries and disciplines. This tripartite approach will increase
the efficacy of research efforts and develop technologies that are optimized for use as
PAT systems. Through a focused effort on developing the appropriate systems and
organizational capabilities necessary to optimize the use of PAT, biopharmaceutical
manufacturers will be poised to overcome the challenges currently facing the industry.
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Chapter 6
Industry Implications and
Conclusion
Numerous market pressures are urging the biopharmaceutical industry to abandon
operating regimes associated with the historical blockbuster-oriented business model,
such as a focus on building capacity. In turn, these pressures are encouraging a
greater emphasis on on operational excellence. Biopharmaceutical manufacturers
and regulatory agencies are assessing how these pressures will change the landscape of
biopharmaceutical manufacturing, and they have concluded that Process Analytical
Technology (PAT) is a crucial component of a plan to increase yield, quality, and
knowledge in coming years.
The implementation of PAT will have significant implications for the biopharma-
ceutical industry, particularly in terms of operations. The first major implication will
be assessing and filling gaps in the skill level of personnel. Effective process analysis
will not significantly increase the amount of data acquired for the sake of having more
data, but will significantly increase the amount of process data relevant to managing
risk. Even in the ideal case, the increase in relevant data will require the industry
to train and hire people who are capable of analyzing, processing, and making sound
judgments based on this data. This change in skills required to effectively manufac-
ture biopharmaceuticals will require the industry to adapt its workforce accordingly.
Consequently, not only will industry need to enhance its ability to train and obtain
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these abilities, but educational institutions will need to continually improve curricula
to supply the market with skilled personnel.
Another important industry implication resulting from the increase in the use of
PAT involves the systems that support, maintain, and transmit the process analysis
information. For example, biological processes are known for having a higher number
of measurable input parameters, process variables, and output characteristics than
many other process industries. However, the measurements of process variables and
output characteristics can be slow and difficult to perform reliably. In contrast,
many of the information systems and automation platforms currently available to the
biopharmaceutical industry have been designed using a philosophy better suited to
other industries. Therefore, to ensure that PAT delivers value, the biopharmaceutical
industry needs to ensure that information systems and automation platforms are
designed to accommodate its manufacturing process. These systems will need to be
capable of handling the high number of variables and unique forms of measurement
characteristic of biopharmaceutical manufacturing.
Because these changes are still occurring in the biopharmaceutical industry, it is
generally accepted that current methods for measuring and quantify biological pro-
cesses are limited and the lack of sufficiently robust methods is slowing discovery of
beneficial therapeutics. We believe that by emphasizing and investing in Process Ana-
lytical Technology, both biopharmaceutical manufacturing and bioanalytical sciences
can benefit from the ensuing developments. It sometimes seems counterintuitive that
large-scale commercial manufacturing can be a source of innovation and expanded
knowledge because it can be perceived as cumbersome and rote. However, certain
aspects of manufacturing, such as high volumes and the drive for consistent quality,
have historically enabled analytical tools to provide and confirm valuable insights
into the critical attributes of processes and products that otherwise would have gone
unnoticed.
Process Analytical Technology, in many ways, is still in the early stages of imple-
mentation in the biopharmaceutical industry even a decade after concerted initiatives
by regulatory agencies. As we have noted in previous chapters, there are challenges
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and limitations associated with the implementation of PAT systems, and such chal-
lenges also accompany research into new possibilities. However, in spite of these
difficulties, the quantifiable benefits of effectively deploying analytical technology in
industrial processing are well documented. By appropriately identifying, evaluating,
and implementing PAT systems, the biopharmaceutical industry can ensure that it
continues to supply valuable therapies to the patients who need them.
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Appendix A
Supplemental Information
This appendix contains supplemental information for the experiments conducted dur-
ing this research. The tabulated data for each run shows only the relevant data from
the beginning of detectable protein elution until the accumulated material contains
approximately 3–4% HMWS. Run 1 had a flow rate of 0.8 L/min, while the other
runs were maintained at a flow rate of 2 L/min. Run 2 is not included in Figure 3-10
because it is an outlier.
Also, for Run 4 we did not back-calculate LS prior to peak max; we had fully
automated the calculation routine by that run so that M was only calculated by
the DCS system once peak max was reached. The % HMWS in pool measurements
have a method RSD of 3.87%, but additional error could arise from mixing collected
sample vials as described in Section 3.4.3. Similarly to Section 3.4.4, in this appendix
UV = UV
UV,maximum
, IS =
IS
IS ,maximum
, and M = M
M,monomer
, making them unitless
quantities.
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Time (hr) UV IS M % HMWS in pool
0.00 0.090 0.090 1.000 0.100
0.05 0.593 0.594 1.002 0.186
0.10 0.850 0.849 0.998 0.137
0.15 0.963 0.963 1.000 0.163
0.20 0.996 0.996 1.000 0.174
0.25 1.000 1.000 1.000 0.180
0.30 0.979 0.979 1.000 0.203
0.35 0.940 0.940 1.000 0.249
0.40 0.880 0.878 0.999 0.306
0.45 0.801 0.798 0.997 0.358
0.50 0.716 0.712 0.995 0.413
0.55 0.622 0.622 1.001 0.523
0.60 0.502 0.518 1.030 0.750
0.65 0.369 0.419 1.136 1.206
0.70 0.273 0.361 1.323 1.977
0.75 0.210 0.314 1.492 2.875
0.80 0.158 0.257 1.621 3.715
0.85 0.118 0.206 1.747 4.322
Table A.1: Tabulated experimental data from run 1
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Time (hr) UV IS M % HMWS in pool
0.00 0.231 0.235 1.017 0.000
0.05 0.533 0.554 1.039 0.080
0.10 0.736 0.749 1.017 0.091
0.15 0.875 0.882 1.008 0.095
0.20 0.926 0.925 0.998 0.097
0.25 0.964 0.960 0.996 0.097
0.30 0.979 0.973 0.994 0.098
0.35 1.000 1.003 1.003 0.098
0.40 0.991 0.995 1.004 0.098
0.45 0.980 0.987 1.007 0.099
0.50 0.977 0.983 1.006 0.099
0.55 0.978 0.988 1.010 0.109
0.60 0.961 0.969 1.008 0.108
0.65 0.951 0.967 1.016 0.116
0.70 0.925 0.938 1.015 0.122
0.75 0.861 0.888 1.032 0.128
0.80 0.781 0.810 1.038 0.132
0.85 0.675 0.707 1.047 0.141
0.90 0.544 0.578 1.062 0.152
0.95 0.414 0.435 1.050 0.166
1.00 0.327 0.348 1.064 0.192
1.05 0.267 0.297 1.114 0.247
1.10 0.234 0.294 1.258 0.374
1.15 0.221 0.316 1.427 0.654
1.20 0.207 0.333 1.603 1.122
1.25 0.171 0.305 1.778 1.751
1.30 0.138 0.249 1.808 2.390
1.35 0.118 0.233 1.972 2.917
1.40 0.101 0.215 2.131 3.371
Table A.2: Tabulated experimental data from run 2
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Time (hr) UV IS M % HMWS in pool
0.00 0.079 0.091 1.150 0.200
0.05 0.393 0.406 1.034 0.283
0.10 0.709 0.713 1.006 0.356
0.15 0.897 0.897 1.000 0.376
0.20 0.967 0.961 0.994 0.384
0.25 0.983 0.982 0.998 0.388
0.30 0.992 0.987 0.995 0.390
0.35 0.999 0.999 0.999 0.392
0.40 0.972 0.973 1.001 0.393
0.45 0.962 0.968 1.007 0.394
0.50 0.967 0.968 1.001 0.395
0.55 0.948 0.953 1.006 0.405
0.60 0.940 0.946 1.006 0.413
0.65 0.927 0.933 1.006 0.420
0.70 0.893 0.898 1.007 0.433
0.75 0.845 0.843 0.998 0.450
0.80 0.791 0.788 0.996 0.469
0.85 0.724 0.720 0.994 0.490
0.90 0.666 0.663 0.995 0.521
0.95 0.599 0.598 0.998 0.564
1.00 0.549 0.550 1.002 0.633
1.05 0.482 0.486 1.009 0.765
1.10 0.403 0.425 1.055 0.988
1.15 0.322 0.376 1.169 1.347
1.20 0.269 0.353 1.310 1.837
1.25 0.233 0.335 1.438 2.403
1.30 0.195 0.299 1.528 2.871
1.35 0.164 0.270 1.645 3.285
1.40 0.143 0.252 1.762 3.625
Table A.3: Tabulated experimental data from run 3
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Time (hr) UV IS M % HMWS in pool
0.00 0.059 0.100
0.05 0.388 0.192
0.10 0.683 0.197
0.15 0.862 0.198
0.20 0.910 0.199
0.25 0.930 0.199
0.30 0.943 0.199
0.35 0.965 0.199
0.40 0.969 0.200
0.45 0.976 0.200
0.50 0.995 0.998 1.003 0.200
0.55 0.984 0.992 1.009 0.200
0.60 0.956 0.964 1.009 0.209
0.65 0.925 0.935 1.010 0.217
0.70 0.877 0.877 1.000 0.223
0.75 0.792 0.791 0.998 0.234
0.80 0.710 0.705 0.993 0.242
0.85 0.632 0.625 0.988 0.254
0.90 0.559 0.551 0.984 0.271
0.95 0.494 0.487 0.986 0.317
1.00 0.444 0.439 0.989 0.392
1.05 0.388 0.392 1.010 0.530
1.10 0.328 0.349 1.064 0.784
1.15 0.282 0.332 1.176 1.211
1.20 0.247 0.326 1.320 1.772
1.25 0.218 0.315 1.443 2.388
1.30 0.187 0.285 1.527 2.927
1.35 0.158 0.257 1.622 3.395
1.40 0.130 0.224 1.722 3.786
Table A.4: Tabulated experimental data from run 4
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Appendix B
Recommended Reading
This appendix contains recommended reading for those looking for introductory mate-
rials about the various aspects of Process Analytical Technology in biopharmaceutical
manufacturing.
Behme, S. Manufacturing of Pharmaceutical Proteins: From Technology to Econ-
omy ; Wiley-VCH: Weinheim, Germany, 2009.
Food and Drug Administration. Pharmaceutical cGMPs for the 21st Century - A
Risk-Based Approach: Final Report. September 2004.
Food and Drug Administration. Guidance for Industry: PAT A Framework
for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance.
September 2004.
Goldratt, E.; Cox, J. The Goal: A Process of Ongoing Improvement, 3rd ed.;
North River Press: Great Barrington, MA, 2012.
Juran, J. M.; De Feo, J. A. Juran’s Quality Handbook: The Complete Guide to
Performance Excellence, 6th ed.; McGraw-Hill: New York, 2010.
Quality by Design for Biopharmaceuticals: Principles and Case Studies ; Rathore,
A. S., Mhatre, R., Eds.; John Wiley & Sons: Hoboken, NJ, 2009.
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